Neurocrine Biosciences, Inc. $NBIX Shares Sold by Fiera Capital Corp

Fiera Capital Corp cut its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 479,676 shares of the company’s stock after selling 10,918 shares during the period. Fiera Capital Corp owned about 0.48% of Neurocrine Biosciences worth $67,337,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its stake in shares of Neurocrine Biosciences by 59.6% in the second quarter. JPMorgan Chase & Co. now owns 4,261,747 shares of the company’s stock worth $535,659,000 after buying an additional 1,590,749 shares during the last quarter. Norges Bank purchased a new stake in Neurocrine Biosciences in the 2nd quarter worth approximately $122,278,000. Los Angeles Capital Management LLC grew its stake in shares of Neurocrine Biosciences by 19,454.9% during the 2nd quarter. Los Angeles Capital Management LLC now owns 744,650 shares of the company’s stock worth $93,595,000 after purchasing an additional 740,842 shares during the period. AQR Capital Management LLC grew its stake in shares of Neurocrine Biosciences by 40.5% during the 2nd quarter. AQR Capital Management LLC now owns 1,510,015 shares of the company’s stock worth $189,794,000 after purchasing an additional 435,385 shares during the period. Finally, Adage Capital Partners GP L.L.C. purchased a new position in shares of Neurocrine Biosciences during the 2nd quarter valued at approximately $42,933,000. 92.59% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director George J. Morrow sold 15,000 shares of the stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $143.37, for a total value of $2,150,550.00. Following the completion of the sale, the director owned 7,068 shares in the company, valued at approximately $1,013,339.16. This represents a 67.97% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Leslie V. Norwalk sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $152.23, for a total value of $761,150.00. Following the transaction, the director owned 7,429 shares in the company, valued at approximately $1,130,916.67. This represents a 40.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 61,966 shares of company stock valued at $8,625,166. Corporate insiders own 4.80% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on NBIX shares. Truist Financial dropped their price target on shares of Neurocrine Biosciences from $169.00 to $140.00 and set a “buy” rating on the stock in a research report on Tuesday. Wedbush lifted their price target on Neurocrine Biosciences from $149.00 to $151.00 and gave the company an “outperform” rating in a research note on Thursday, February 12th. Canaccord Genuity Group lifted their price target on Neurocrine Biosciences from $160.00 to $164.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. BMO Capital Markets lowered their price target on Neurocrine Biosciences from $147.00 to $140.00 and set a “market perform” rating on the stock in a research report on Thursday, February 12th. Finally, Piper Sandler boosted their price objective on Neurocrine Biosciences from $175.00 to $179.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. Sixteen equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and an average price target of $175.84.

Neurocrine Biosciences Price Performance

Shares of Neurocrine Biosciences stock opened at $130.10 on Friday. The business has a 50 day simple moving average of $137.94 and a two-hundred day simple moving average of $140.27. The stock has a market capitalization of $13.06 billion, a P/E ratio of 27.92, a PEG ratio of 0.67 and a beta of 0.31. Neurocrine Biosciences, Inc. has a 12 month low of $84.23 and a 12 month high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Wednesday, February 11th. The company reported $1.88 EPS for the quarter, missing the consensus estimate of $2.36 by ($0.48). Neurocrine Biosciences had a net margin of 16.73% and a return on equity of 16.48%. The firm had revenue of $805.50 million during the quarter, compared to analyst estimates of $804.21 million. During the same period in the prior year, the company posted $1.69 earnings per share. The firm’s revenue for the quarter was up 28.3% compared to the same quarter last year. As a group, research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.